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Matrix metalloproteinases (MMPs) are pleiotropic endopeptidases involved in a variety
of neurodegenerative/neuroinflammatory processes through their interactions with a
large number of substrates. Among those, the amyloid precursor protein (APP) and the
beta amyloid peptide (Aβ) are largely associated with the development of Alzheimer’s
disease (AD). However, the regulation and potential contribution of MMPs to AD remains
unclear. In this study, we investigated the evolution of the expression of MMP-2, MMP-9,
and membrane-type 1-MMP (MT1-MMP) in the hippocampus at different stages of
the pathology (asymptomatic, prodromal-like and symptomatic) in the 5xFAD transgenic
mouse AD model. In parallel we also followed the expression of functionally associated
factors. Overall, the expression of MMP-2, MMP-9, and MT1-MMP was upregulated
concomitantly with the tissue inhibitor of MMPs-1 (TIMP-1) and several markers
of inflammatory/glial response. The three MMPs exhibited age- and cell-dependent
upregulation of their expression, with MMP-2 and MMP-9 being primarily located to
astrocytes, and MT1-MMP to neurons. MMP-9 and MT1-MMP were also prominently
present in amyloid plaques. The levels of active MT1-MMP were highly upregulated in
membrane-enriched fractions of hippocampus at 6 months of age (symptomatic phase),
when the levels of APP, its metabolites APP C-terminal fragments (CTFs), and Aβ
trimers were the highest. Overexpression of MT1-MMP in HEK cells carrying the human
APP Swedish mutation (HEKswe) strongly increased β-secretase derived C-terminal APP
fragment (C99) and Aβ levels, whereas MMP-2 overexpression nearly abolished Aβ
production without affecting C99. Our data consolidate the emerging idea of a regulatory
interplay between MMPs and the APP/Aβ system, and demonstrate for the first time the
pro-amyloidogenic features of MT1-MMP. Further investigation will be justified to evaluate
this MMP as a novel potential therapeutic target in AD.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common and devastating
neurodegenerative disorder. Histopathologically, AD is charac-
terized by the accumulation of intracellular and extracellular
deposits of amyloid beta peptide (Aβ), which according to the
amyloid cascade hypothesis is considered as a crucial process
in AD pathogenesis (Hardy and Higgins, 1992; Karran et al.,
2011). Amyloid beta peptide results from the sequential cleavage
of the amyloid precursor protein (APP) by β- and γ-secretases. Its
clearance is in part mediated by Aβ-degrading metalloproteinases,
including neprilysin (NEP), insulin-degrading enzyme (IDE),
angiotensin-converting enzyme (ACE), endothelin-converting
enzyme (ECE) and matrix metalloproteinases (MMPs; De
Strooper, 2010; Rivera et al., 2010; Chami and Checler, 2012).
Matrix metalloproteinases constitute a family of ∼25 zinc-
dependent endopeptidases produced by all neural cell types.
They interact with a wide range of substrates (e.g., extracel-
lular matrix proteins, cytokines, growth factors, cell adhesion
molecules, receptors), which confer to MMPs broad functional
diversity (Rivera et al., 2010). They are thus involved in numerous
pathological and physiological processes: neural cell motility and
outgrowth (Ogier et al., 2006; Gonthier et al., 2007; Ould-yahoui
et al., 2009), neuronal death (Jourquin et al., 2003), synaptic
plasticity and cognition (Jourquin et al., 2005; Chaillan et al.,
2006; Meighan et al., 2006; Nagy et al., 2006; Kaliszewska et al.,
2012), neuroinflammation (Ogier et al., 2005; Hu et al., 2007;
Candelario-Jalil et al., 2009) and blood brain barrier (BBB)
breakdown (Yang et al., 2007).
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Several MMPs, including MMP-2, MMP-9 and membrane-
type 1-MMP (MT1-MMP), a principal activator of MMP-2,
may degrade Aβ (Roher et al., 1994; Backstrom et al., 1996;
Yin et al., 2006; Liao and Van Nostrand, 2010). In return, Aβ
upregulates the expression of MMP-2 and/or MMP-9 in cultured
neurons, (Mizoguchi et al., 2009), astrocytes (Deb et al., 2003),
and neuroblastoma cells (Talamagas et al., 2007). MT1-MMP
expression is upregulated in cultured human cerebrovascular
smooth muscle cells upon prolonged treatment with pathogenic
concentrations of Aβ (Jung et al., 2003). Moreover, MMP-2 and
MT1-MMP have been suggested to cleave APP in cellulo and
generate soluble truncated APP forms with yet unknown func-
tions (LePage et al., 1995; Higashi and Miyazaki, 2003; Ahmad
et al., 2006). In vivo, MMP-2 and MMP-9 expression is upreg-
ulated in reactive astrocytes of the Tg2576 transgenic mouse
model of AD at advanced stages of the pathology concurrent
with massive amyloid deposition (Yin et al., 2006). However,
the evolution of MMPs expression from asymptomatic to symp-
tomatic phases is unknown, and yet it may provide valuable
insights on the role of these proteinases in AD. From previ-
ous work (Oakley et al., 2006; Jawhar et al., 2012; Giannoni
et al., 2013; Girard et al., 2013), the 5xFAD mouse model of
AD has been shown to recapitulate within the first 6 months
of life asymptomatic, prodromal-like and symptomatic phases
reminiscent of AD pathology. Accordingly, we have investigated
the brain distribution of MMP-2, MMP-9 and MT1-MMP at 2,
4 and 6 months, each time point corresponding to these three
phases, respectively. Our data clearly indicate specific patterns of
spatio-temporal distribution for these MMPs along with changes
in inflammatory factors and Aβ-degrading enzymes. Our study
also reveals that the level of MT1-MMP increases with age in
5xFAD hippocampus, in pace with the increase of APP and its C-
terminal fragments (CTFs), and Aβ trimers. We found in cellulo
that MT1-MMP overexpression enhanced the β-secretase-derived
CTF (C99) and Aβ production, and thus conclude that MT1-
MMP could be a new pro-amyloidogenic proteinase and a novel
target in AD pathogenesis.
METHODS
ANIMALS
Experiments were performed in transgenic hemizygous 5xFAD
male mice and their wild-type (WT) littermates (Jackson Labo-
ratories, Bar Harbor, ME, USA) on a C57BL6/SJL background.
5xFAD mice harbor three familial Alzheimer’s disease (FAD)
mutations in the human APP695 (Swedish K670N, M671L;
Florida I716V and London V717I) and two mutations in the
human presenilin-1 (PSEN-1) (M146L, L286V) under the tran-
scriptional control of the neuron-specific mouse Thy-1 promoter.
These mice show over a 6- to 9-month period intracellular and
extracellular accumulation of Aβ42, gliosis, synaptic demise, cog-
nitive impairment and neuronal loss (Oakley et al., 2006; Ohno
et al., 2007; Girard et al., 2013). Behavioral dysfunctions have
been primarily described in 5xFAD females (Jawhar et al., 2012),
which present a more prominent amyloid pathology than males.
However, recent behavioral data obtained using olfactory-based
tests, have uncovered subtle deficits of cortical- and hippocampal-
dependent cognition in males as early as 4 months that are absent
at 2 months and are more severe at 6 months (Girard et al.,
2013, 2014). Another study has also highlighted hippocampal-
dependent spatial memory deficits in 5-month-old 5xFAD males
in the Morris water maze (Hongpaisan et al., 2011). Taken
together, these data indicate an age-dependent progression of
functional deficits in 5xFAD mice that affect the hippocampus
and roughly correspond to the asymptomatic, prodromal-like and
symptomatic phases of the pathology at 2, 4 and 6 months of
age, respectively. Accordingly, these time points were chosen to
investigate the evolution of MMPs and other molecular systems
in 5xFAD males. Procedures were conducted in accordance with
National and European regulations (EU directive N◦ 2010/63) and
in agreement with the authorization for animal experimentation
attributed to the laboratory by the Prefecture des Bouches du
Rhône (permit number: D 13 055 08). All efforts were made to
minimize animal suffering and to reduce the number of mice
used.
GENOTYPING
Newborn pups were genotyped by polymerase chain reaction
(PCR). Genomic DNA was isolated from tail biopsies using 60
µL of lysis buffer (25 mM NaOH, 0.2 mM EDTA) at 100◦C for
30 min. Samples were then cooled to −20◦C for 5 min and 60
µL of 40 mM Tris-HCl buffer was added to neutralize the lysis
reaction. Five µL of DNA were amplified with PSEN-1 primers by
a classic PCR reaction: denaturation for 5 min at 95◦C, followed
by 40 cycles each consisting of 94◦C for 3 min, 55◦C for 45 s
and 72◦C for 1 min (Jackson Laboratories). PCR products were
separated by electrophoresis in a 1.5% agarose gel containing
ethidium bromide and visualized under UV light lamp.
PLASMID CONSTRUCTIONS
MT1-MMP and MMP-2 cDNAs were amplified by PCR from
P15 C57Bl6 mice cerebellum mRNA, and cloned and expressed
as previously reported for other MMP cDNAs (Sbai et al.,
2008, 2010; Ould-yahoui et al., 2009). The following forward
(For) and reverse (Rev) primers were used: MT1For AAT TAT
GGA TCC CGG ACC TTG TCC AGC AGC GAA C, MT1Rev
TAT ATA CTC GAG AGG AGA GCA GAG AGG GCT TC,
MMP-2For ATA TAT GAA TTC GCC AGA GAC CTC AGG
GTG ACA CGC and MMP-2Rev ATA TAT GTC GAC AGG
CAG CCC AGC CAG TCT GAT TTG AT. All constructs
were cloned into pEGFP-N1 (Clontech, Saint-Germain-en-Laye,
France). Plasmids coding for GFP-, MT1-MMP, and MMP-2
were amplified in E. coli DH5α (Life Technologies, Saint Aubin,
France) and purified using the NucleoBond Xtra Midi Plus EF
(Macherey-Nagel, Hoerd, France) according to manufacturer’s
recommendations.
HEKswe CELL CULTURE AND Aβ PRODUCTION
HEK cells stably transfected with pcDNA3 vector overexpressing
human APP harboring the double Swedish mutation (HEK-
swe) were used (Chevallier et al., 1997). Cells were plated to
1× 106 cells/mL for 24 h in 6-well plates in DMEM Gluta-
max, FBS 10%, penicillin/streptomycin 1% (Life Technologies).
The cells were transfected with 1 µg of plasmids coding for
MT1-MMP/GFP or MMP-2/GFP fusion proteins using the Jet
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Table 1 | Summary of TaqMan mouse probes used for quantitative
PCR.
Gene Gene description Probes ID
name
Mmp-2 Matrix metalloproteinase 2 Mm 00439498-m1
Mmp-9 Matrix metalloproteinase 9 Mm 00442991-m1
Mt1-mmp Membrane-type 1 matrix Mm 00485054-m1
metalloproteinase
Timp-1 Tissue inhibitor of matrix Mm 00441818-m1
metalloproteinase 1
Timp-2 Tissue inhibitor of matrix Mm 00441825-m1
metalloproteinase 2
Timp-3 Tissue inhibitor of matrix Mm 00441826-m1
metalloproteinase 3
Timp-4 Tissue inhibitor of matrix Mm 00446568-m1
metalloproteinase 4
Adam-10 A disintegrin and Mm 00545742-m1
metalloproteinase 10
Adam-17 A disintegrin and Mm 00456428-m1
metalloproteinase 17
Nep Neprilysin Mm 00485028-m1
Ace Angiotensin-converting enzyme Mm 00802048-m1
Ece Endothelin-converting enzyme Mm 01187091-m1
Ide Insulin-degrading enzyme Mm 00473077-m1
Il1b Interleukin-1 beta Mm 01336189-m1
Ccl2 Chemokine ligand 2 Mm 00441242-m1
Gfap Glial fibrillary acidic protein Mm 01253033-m1
Emr1 F4/80, marker for mouse Mm 00802529-m1
macrophages
Gapdh Glyceraldehyde-3-phosphate Mm 99999915-g1
dehydrogenase
Probes are provided by Applied Biosystems.
Pei transfection reagent (Ozyme, Saint-Quentin en Yvelines,
France), as previously described (Sbai et al., 2010). Twelve hours
after transfection, the medium was replaced with OptiMEM
containing 1% ITS (Life Technologies) and cells were allowed
to secrete for 48 h. Human Aβ40 peptide levels were mea-
sured in the culture supernatants using an ELISA assay (Life
Technologies).
REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN
REACTION (RT-QPCR)
Total RNA was extracted from mice hippocampi using the
Nucleospin RNA II kit (Macherey-Nagel) according to the
manufacturer’s instructions. cDNA was synthesized from 500
ng of RNA using random primers (Life Technologies) and
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV
RT, Life Technologies) in a total volume of 50 µL. Twenty-
five ng of cDNA were submitted to qPCR reaction. All the
probes used in this study are represented in Table 1. Gapdh
gene expression was used as an endogenous control for eval-
uation of all mRNA levels. qPCR was performed using the
Fast Real-Time PCR System according to the manufacturer’s
recommendations (Applied Biosystems, Life Technologies). For
each experiment, four different cDNA samples were analyzed
in duplicate. Relative gene expression was obtained using the
comparative 2−(∆∆Ct) method after normalization to the Gapdh
housekeeping gene.
IMMUNOHISTOCHEMISTRY
Mice were anesthetized with pentobarbital (0.36 g/kg) and tran-
scardially perfused with 50 mL of NaCl 0.9% followed by 50 mL
of 4% paraformaldehyde (PFA). Mice brains were then removed
and post-fixed for 24 h in PFA at 4◦C. Coronal sections (30 µm
thick) were obtained using a vibratome (Microm HM 650 V,
Thermo scientific, MA, USA), and stored at −20◦C in cryopro-
tectant containing 30% glycerol, 30% ethylene glycol and 40%
phosphate buffer 0.5 M pH 7.4. Free-floating sections were first
permeabilized and binding blocked for 1 h at room tempera-
ture using a solution of PBS 1X, 0.1% Triton X-100 and 3%
Bovine Serum Albumin (BSA, Sigma-Aldrich, Saint Quentin-
Fallavier, France). Sections were then incubated overnight at 4◦C
with primary antibodies (see Table 2), followed by Alexa 488-
goat anti-rabbit (1/500) or Alexa 594-goat anti-mouse (1/500)
(both from Life Technologies) for 1 h at room temperature.
Nuclei were stained with Hoechst (0.5 µg/mL, Life Technolo-
gies). Omission of the primary antibody was used as control
and no immunostaining was observed. Sections were mounted
using Prolong Gold Antifading reagent on Superfrost glass slides
(Life Technologies). Images were taken and processed using a
confocal microscope (LSM 700) and Zen software (Zeiss, Jena,
Germany).
IN SITU ZYMOGRAPHY
In situ zymography was performed as previously described, with
slight modifications (Jourquin et al., 2005). After anesthesia and
NaCl perfusion (see above), the brain was removed from the skull
and snap frozen in cold isopentane. Coronal brain sections (30
µm thick) were obtained with a cryostat (CM 3050 LEICA, Ger-
many), collected on Superfrost Plus®slides and stored at −80◦C.
Brain sections were incubated with 20 µg/ml FITC-gelatin (Life
Technologies) for 1 h at 37◦C in a dark humidified chamber,
rinsed in PBS, fixed with PFA for 30 min, and immunostained
with 6E10 specific anti-Aβ antibody (see Table 2). Images were
analyzed as described above.
WESTERN BLOTTING
After NaCl transcardial perfusion, the hippocampi were microdis-
sected and snap-frozen for biochemical assays. For western blots
(WB), each sample was homogenized in 25% w/v of 50 mM
Tris-HCl pH 7.5 buffer containing 150 mM NaCl, 2 mM EDTA,
1% Triton X-100, 0.05% SDS and proteinase inhibitor cocktail
(Millipore, Molsheim, France) and centrifuged at 10,000× g
for 20 min to obtain the “soluble fraction”. Cell pellets were
resuspended in 25% w/v of 50 mM Tris-HCl pH 7.5 buffer
containing 2% SDS, then sonicated and centrifuged at 10,000× g
for 20 min to obtain the insoluble “membrane-enriched fraction”.
Protein concentrations were determined using a Bio-Rad DCTM
protein assay kit (Bio-Rad, Marnes-La-Coquette, France), and
50 µg of protein were run on 10% to 15% SDS-PAGE gels and
transferred to nitrocellulose membranes (Amersham Bioscience,
Velizy-Villacoublay, France). After blocking, membranes were
probed with primary antibodies, as indicated in Table 2 and
then incubated with the corresponding horseradish peroxidase-
conjugated secondary IgG antibodies (Jackson Immunoresearch,
Suffolk, UK). Immunodetection was performed using the ECL
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Table 2 | Detail of primary and secondary antibodies used for western blot and immunohistochemistry in this study.
Dilution Dilution
Antigens Species WB IHC Company 2nd Antibody WB IHC
MMP-2 Rabbit 1/250 1/200 Millipore Goat anti Rabbit 1/1000 1/500
MMP-9 Rabbit 1/500 1/200 Millipore Goat anti Rabbit 1/1000 1/500
MT1-MMP Rabbit 1/500 1/100 Abcam Goat anti Rabbit 1/500 1/500
TIMP-1 Goat 1/300 x R&D systems Donkey anti Goat 1/500 x
TIMP-2 Mouse 1/1000 x Abcam Goat anti Mouse 1/2000 x
APP 22C11 Mouse 1/500 x Millipore Goat anti Mouse 1/2000 x
Aβ 6E10 Mouse 1/300 1/300 Covance Goat anti Mouse 1/500 x
APP-CTF Rabbit 1/2000 x Sigma Goat anti Rabbit 1/4000 x
GFP Mouse 1/1000 x Roche Goat anti Mouse 1/3000 x
GFAP Mouse x 1/200 Millipore Goat anti Mouse x 1/500
MAP-2 Chicken x 1/200 Abcam Donkey anti Chicken x 1/500
GAPDH Mouse 1/2000 x Millipore Goat anti Mouse 1/8000 x
Actin Mouse 1/5000 x Sigma Goat anti Mouse 1/10000 x
Horse radish peroxydase (HRP) coupled secondary antibodies (Jackson Immunoresearch) were used for western blot (WB). Alexa-coupled secondary antibodies
(Invitrogen) were used for immunohistochemistry (IHC).
kit according to the manufacturer’s instructions (GE Healthcare,
Dutscher, Brumath, France), and optical density measured using
the imageJ software (NIH). All optical density plots represent
normalized values to actin or GAPDH as indicated in the figure
legends.
STATISTICS
All values represent the means ± SEM of the number of animals
or independent cultures indicated in the figure legends. Student-t
test was used to compare two groups. ANOVA analysis followed by
a Tukey’s post hoc test was used to compare more than two groups.
Statistical significance was set up to p < 0.05. Analyses were
performed with the Kaleidagraph software (Synergy Software,
Reading PA, USA).
RESULTS
EXPRESSION OF METALLOPROTEINASES, TIMPs AND INFLAMMATORY
MARKERS IN THE HIPPOCAMPUS OF 5xFAD MICE ACROSS AGE
To obtain a broad picture of the regulation of metallopro-
teinases potentially involved in Aβ/APP metabolism across dif-
ferent phases of the amyloid pathology, we assessed the mRNA
levels of MMPs, adamalysins 10 and 17 (ADAM-10 and -17)
and classical Aβ-degrading enzymes (NEP, IDE, ACE, ECE). In
addition, we also measured the mRNA levels of tissue inhibitor of
MMPs (TIMPs), the natural inhibitors of MMPs and ADAMs, and
a number of prototypic inflammatory markers (Figures 1A–E).
Among MMPs, the expression of Mmp-2 and Mmp-9 remained
unaffected in 2-month-old mice and was significantly increased
50% and 130% in 5xFAD mice compared to WT at 4 and 6
months, respectively (Figure 1A). Mt1-mmp showed a significant
increase of 50% only at 6 months. In contrast, the levels of
Adam-10 and Adam-17 remained stable between genotypes, but
increased and decreased respectively at 6 months as compared
to previous time points for the same genotype (Figure 1B).
The expression of major Aβ-degrading enzymes did not differ
significantly between 5xFAD and WT mice, with the exception
of Nep, which showed significant decreases (30%) at 2 and 4
months (Figure 1C). Among the four TIMPs, Timp-1 exhibited
strong 4 and 5-fold increases at 4 and 6 months, respectively.
The expression of Timp-2 significantly decreased at 2 months
and increased at 4 months. The level of Timp-3 mRNA decreased
at 2 and 6 months while it increased at 4 months. No dif-
ferences were observed between WT and 5xFAD for Timp-4
(Figure 1D). Specific markers of astrocyte (Gfap) and microglia
(F4/80) reactivity remained stable at 2 months and signifi-
cantly increased at 4 and 6 months. Furthermore, the levels of
the pro-inflammatory mediators interleukin-1beta (Il-1β) and
chemokine ligand 2 (Ccl2) (also known as monocyte chemoat-
tractant protein-1 (Mcp-1), were already upregulated 2.6-fold
in 5xFAD brains as early as 2 months of age, illustrating an
early inflammatory response in these mice before the appearance
of the first cognitive deficits. By 4 and 6 months, Il-1β levels
reached a 12-fold increase compared to WT. Ccl2 reached a peak
of expression by 6 months (7-fold) (Figure 1E). Overall, the
MMP/TIMP system seems to be more affected (mostly upreg-
ulated) than the ADAMs or the Aβ-degrading enzyme subfam-
ilies. The upregulation of MMP and TIMP levels occur at 4
months of age, coincident with the upregulation of markers of
glial reactivity and in the context of an ongoing upregulation
of inflammatory markers that precedes changes in all other
genes.
MMPs AND TIMPs CONTENT IN THE HIPPOCAMPUS OF 5xFAD AND
WT MICE ACROSS AGE
MMP levels from hippocampal soluble and membrane-enriched
fractions were analyzed by WB. In the soluble fraction, MMP-
2 levels did not change with age in WT mice, whereas MMP-9
exhibited a significant decrease (35%) between 2 and 4–6 months
(Figure 2A). In 5xFAD mice, the levels of both MMPs increased
significantly at 4 months of age compared to 2 months. For
MMP-9, this increase was also significant when compared to 6
months. Moreover, we found that MMP-2 and MMP-9 levels were
increased in 5xFAD compared to WT only at 4 months by a
30% and 67%, respectively. We observed no changes in MMP-
2 and MMP-9 levels between genotypes at 2 or 6 months. An
additional faint band (∼90 kDa) compatible with the expected
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FIGURE 1 | mRNA expression of different proteolytic systems and
inflammatory markers across age in 5xFAD mice hippocampi. mRNA
expression for MMPs (A) ADAMs (B) Aβ-degrading enzymes (C), TIMPs
(D) and inflammatory markers (E) was analyzed in the hippocampus of
WT and 5xFAD mice at 2, 4 and 6 months. Values are the mean ± SEM of
four mice per group representing fold change differences between
genotypes. *p < 0.05, **p < 0.01, ***p < 0.001 when comparing 5xFAD
vs. WT of the same age; #p < 0.05, ##p < 0.01, ###p < 0.001 when
comparing different ages of the same genotype; ANOVA followed by
Tukey’s test.
size of the active form of MMP-9 was also detected (Figure 2A),
but no significant differences were found across genotypes (data
not shown).
Two immunoreactive bands for anti-MT1-MMP were
observed at ∼65 kDa and ∼55 kDa in the membrane-enriched
fraction (Figure 2B), coincident with the expected size of pro-
MT1-MMP and active MT1-MMP, respectively. No significant
changes were observed for pro-MT1-MMP across age or between
genotypes. In contrast, active MT1-MMP levels in 5xFAD mice
increased 4.5-fold at 6 months compared to 2 and 4 months,
and also to WT at 6 months. In the soluble fraction, where
MT1-MMP was barely detectable, we did not evidence changes
in its expression across age or between genotypes (data not
shown).
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FIGURE 2 | Age-dependent changes in MMPs and TIMPs across age in
5xFAD mice hippocampi. Western blots and the corresponding
quantifications of MMP-2, MMP-9, TIMP-1 and TIMP-2 in the soluble fraction
(A), and of MT1-MMP pro- and active forms in the membrane-enriched
fraction (B) of WT and 5xFAD mice hippocampi at 2, 4 and 6 months of age.
GAPDH normalized values are the mean ± SEM of four mice per group
representing the percentage of variation in optical density (O.D.). *p < 0.05,
**p < 0.01, ***p < 0.001 when comparing 5xFAD vs. WT of the same age;
#p < 0.05, ##p < 0.01, ###p < 0.001 when comparing the same genotype
across age; ANOVA followed by Tukey’s test.
TIMP-1, a major endogenous inhibitor of secreted MMPs
and ADAMs (e.g., ADAM-10), presented 83% higher levels at 4
months in 5xFAD compared to WT hippocampi. Neither WT nor
5xFAD mice showed significant differences in TIMP-1 content
across age. No differences between genotypes were detected in
the levels of TIMP-2, which inhibits MT-MMPs and also secreted
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MMPs. However, TIMP-2 exhibited a remarkable 3-fold increase
in 5xFAD hippocampi at 6 months compared to 2 and 4 months.
It is noteworthy that TIMPs were not detected in the insoluble
fraction (data not shown).
COMPARISON OF MMP-2 EXPRESSION IN THE HIPPOCAMPUS OF WT
AND 5xFAD MICE
To further assess the cellular distribution of MMP-2, MMP-9
and MT1-MMP, coronal brain sections from WT and 5xFAD
mice were immunolabeled using specific MMP antibodies. As
illustrated in the subiculum, weak MMP-2 immunoreactivity was
diffusely distributed in WT hippocampi at 2 months of age
(Figure 3A, upper left). In contrast, MMP-2 staining in 5xFAD
brains was present in glial cells with astrocyte morphology in
the vicinity of incipient amyloid deposits (Figure 3A, lower
left). MMP-2 immunostaining steadily increased at 4 and 6
months in glial cells associated with larger and more numer-
ous amyloid plaques, especially in the hippocampal subiculum,
where amyloid plaques were mainly concentrated (Figure 3A,
lower panels). No MMP-2 immunoreactivity was observed in
amyloid plaques at 2 months. At 4 and 6 months, most amy-
loid plaques exhibited moderate immunoreactivity for MMP-
2 (Figure 3B). Double immunostaining using anti-MMP-2 and
anti-GFAP antibodies confirmed the astrocytic expression of
MMP-2 (Figure 3C).
COMPARISON OF MMP-9 EXPRESSION IN THE HIPPOCAMPUS OF WT
AND 5xFAD MICE
In the subiculum of 2-month-old WT mice, MMP-9 immunos-
taining was confined to neuronal cell bodies (Figure 4A, upper
left). In age-matched 5xFAD mice, MMP-9 immunoreactiv-
ity was detected in both soma and dendrites (Figure 4A,
lower left). By 4 and 6 months, MMP-9 immunostaining in
5xFAD mice was mainly present in reactive astrocytes, whereas
we could no longer detect dendrite-associated immunoreac-
tivity (Figure 4A, lower middle and right panels). Unlike
MMP-2, MMP-9 colocalized with 6E10 immunostaining in
amyloid plaques as early as 2 months, and immunostaining
was very prominent in these amyloid structures at 4 and 6
months (Figure 4B). Double immunostaining using anti-MMP-
9 and anti-GFAP antibodies confirmed the astrocytic expres-
sion of MMP-9 in particular at 4 and 6 months of age
(Figure 4C).
COMPARISON OF MT1-MMP EXPRESSION IN THE HIPPOCAMPUS OF
WT AND 5xFAD MICE
In WT hippocampi, MT1-MMP immunostaining presented a
punctate distribution that localized to neuronal cell layers at
all ages studied (Figure 5A). In the 5xFAD mice, the intensity
of labeling correlated with the density of amyloid load. Thus,
subicular neurons exhibited more prominent MT1-MMP signal
than other areas in the hippocampus (data not shown). Like,
MMP-9, MT1-MMP immunostaining was already present in
amyloid plaques at 2 months, and this colocalization persisted
across time (Figure 5A, lower panels). Double immunostaining
with anti-MAP-2 specific neuronal marker confirmed that MT1-
MMP immunolabeling localized preferentially to neuronal soma
(Figure 5B, upper panels). Double immunostaining with anti-
GFAP antibodies confirmed that MT1-MMP was not expressed
by astrocytes (Figure 5B, lower panels).
MMP-DEPENDENT GELATINOLYTIC ACTIVITY IS PRESENT IN AMYLOID
PLAQUES
A common feature to MMP-2, MMP-9 and MT1-MMP in the
present study is their presence in extracellular amyloid deposits.
The three MMPs have the ability to degrade gelatin (Imai et al.,
1996; Rivera et al., 2002), with MMP-2 and MMP-9 being more
efficient than MT1-MMP. Thus, we used gelatin-based in situ
zymography to determine the distribution of gelatinolytic activ-
ity with respect to Aβ deposits. We found strong gelatinolytic
activity in the hippocampus preferentially associated with amy-
loid plaques. Gelatin-FITC signal was generally more intense in
plaque areas with diffuse amyloid than in those with a dense
core amyloid (Figure 6A, see arrows). Incubation of fresh brain
slices with GM6001, a broad spectrum MMP inhibitor, inhibited
fluorescence signal about 50% (Figure 6B), indicating an impor-
tant contribution of MMPs to proteolytic activity in amyloid
plaques.
AGE-DEPENDENT INCREASE IN THE LEVELS OF APP, APP-CTFs AND Aβ
TRIMERS IN 5xFAD MICE
A progressive increase of soluble and fibrillar Aβ across time has
been previously described in 5xFAD brains (Oakley et al., 2006).
However, we have limited information on the age-dependent
changes in APP and its metabolites APP-CTFs, and Aβ oligomers.
Gaining insight into such evolution may be important to support
a pathophysiological role of APP metabolites and to decipher
possible functional links with MMPs depending on their spatio-
temporal distribution. In this context, the β-secretase-derived
CTF of APP, C99 (βCTF) and small Aβ oligomers (dimers and
trimers) have been shown to be particularly neurotoxic (Walsh
et al., 2002; Cleary et al., 2005; Lesné et al., 2006; Townsend
et al., 2006; Shankar et al., 2008; Lauritzen et al., 2012). As
illustrated in Figure 7, APP levels increased by 2.6-fold in the
soluble fraction of 5xFAD hippocampi at 4 and 6 months of age
compared to WT, as revealed by the 22C11 antibody directed
against the N-terminal domain of APP (Figure 7A). In the
membrane-enriched fraction, the APP C-terminal specific CTF
antibody revealed a significant 3.8-fold increase of full length
APP, as early as 2 months of age, and 5.4-fold increase by 4
and 6 months (Figure 7B). Concomitantly, we found a dramatic
upregulation of β- and α-CTFs (C99 and C83, respectively)
compared to WT at 2 (3.3-fold), 4 (20-fold) and 6 (13-fold)
months. In the same membrane-enriched fraction, the human
Aβ specific 6E10 antibody demonstrated between 15- and 30-fold
increase in the levels of putative Aβ trimers of∼12 kDa in 5xFAD
mice at 4 and 6 months, compared to background levels in the
WT. It is noteworthy that the ∼12 kDa band was not detected
in the membrane enriched fractions at 2 months (Figure 7B)
nor in the soluble fractions, regardless of age (data not shown).
The absence of the ∼12 kDa band in the CTF immunoblot,
together with its detection by the 6E10 antibody, reinforced the
idea that the latter indeed detected Aβ trimers and not a CTF
of APP containing the 6E10 epitope located between the β- and
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FIGURE 3 | Age-dependent upregulation of MMP-2 expression in
astrocytes and amyloid plaques in 5xFAD mice hippocampi. (A) Confocal
microphotographs representative of four animals per group showing
combined immunohistochemistry with the Aβ specific 6E10 antibody (red)
and a MMP-2 specific antibody (green) in the subiculum of WT and 5xFAD
mice at 2, 4 and 6 months of age. Note that MMP-2 is upregulated in neural
cells with astrocyte morphology in the vicinity of amyloid plaques (arrowhead)
as early as 2 months. MMP-2 immunostaining increases with age in 5xFAD
mice, and at 4 and 6 months there is partial colocalization with amyloid
plaques, as revealed by yellow color (arrows). (B) High power magnifications
of 5xFAD subiculum at 2 and 6 months showing non-association and
association of MMP-2 with amyloid deposits, respectively. Hoechst (blue)
labels cell nuclei. (C) Confocal microphotographs showing localization of
MMP-2 (green) to GFAP+ astrocytes (red) of 5xFAD mice. Scale bars: 10 µm.
α-cleavage sites. These data show a clear correspondence between
the upregulation of APP, CTFs and Aβ trimers in the same
membrane-enriched fractions where the levels of active MT1-
MMP were also increased.
MT1-MMP OVEREXPRESSION INCREASES C99 AND Aβ LEVELS IN
HEKswe CELLS
The coincidence between increased levels of active MT1-
MMP, and increased APP metabolism and CTFs accumulation
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FIGURE 4 | Age-dependent upregulation of MMP-9 expression in
astrocytes and amyloid plaques in 5xFAD mice hippocampi. (A)
Confocal microphotographs representative of four animals per group
showing combined immunohistochemistry with the Aβ specific 6E10
antibody (red) and a MMP-9 specific antibody (green) in the subiculum of
WT and 5xFAD mice at 2, 4 and 6 months of age. Note that at 2 months
MMP-9 presents a somato-dendritic distribution in 5xFAD neurons, in
contrast with WT where it is essentially somatic. Also, at 2 months MMP-9
shows incipient localization to amyloid plaques, as revealed by yellow color
(arrows). MMP-9 immunostaining increases with age in astrocytes of
5xFAD mice, and at 4 and 6 months colocalization with amyloid plaques is
noticeable. Hoechst (blue) labels cell nuclei. (B) High power magnifications
of 5xFAD subiculum at 2 and 6 months showing age-dependent increased
association of MMP-9 with amyloid deposits. (C) Confocal
microphotographs showing localization of MMP-9 (green) to GFAP+
astrocytes (red) of 5xFAD mice. Scale bars: 10 µm.
prompted us to investigate if MT1-MMP could contribute to
generate these APP CTFs. To address this point, we transiently
expressed a MT1-MMP/GFP fusion protein in HEKswe cells sta-
bly expressing APP with the Swedish mutation that is also present
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FIGURE 5 | Age-dependent upregulation of MT1-MMP expression in
neurons and amyloid plaques in 5xFAD mice hippocampi. (A) Confocal
microphotographs representative of four animals per group showing
combined immunohistochemistry with the Aβ specific 6E10 antibody (red)
and a MT1-MMP specific antibody (green) in the subiculum of WT and 5xFAD
mice at 2, 4 and 6 months of age. MT1-MMP presents a punctate distribution
in the neuronal cell layer. MT1-MMP immunostaining increases at 6 months in
5xFAD hippocampi and colocalizes with amyloid plaques at all ages studied,
as revealed by yellow color (arrows). Hoechst (blue) labels cell nuclei. (B) High
power magnifications of 5xFAD subiculum showing localization of MT1-MMP
(green) to MAP-2+ neuronal cell bodies (red, upper panels), and no
colocalization with GFAP+ astrocytes (red, lower panels). Scale bars: 10 µm.
in 5xFAD mice. In parallel, we also expressed a MMP-2/GFP
fusion protein in these cells. We found that MT1-MMP/GFP
induced a 6-fold increase in the levels of a 17 kDa band detected
by the CTF antibody compatible with the size of C99 (Figure 8A).
A faint band immediately below, likely representing C83, was
also induced by MT1-MMP/GFP. In contrast with the marked
increase in C99 levels induced by MT1-MMP, the overexpres-
sion of MMP-2/GFP did not affect CTF levels, which remained
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FIGURE 6 | MMP gelatinolytic activity is present in amyloid plaques.
(A) Confocal microphotographs representative of four animals per group
showing combined immunohistochemistry using the Aβ specific 6E10
antibody (red) and gelatin-FITC in situ zymography (green) in the
hippocampus of 6-month-old 5xFAD mouse. Note that zones of perfect
colocalization (arrows, yellow color) coexist with zones of poor or
non-colocalization (arrowheads), often associated with dense core amyloid.
(B) Confocal microphotographs showing reduction of gelatinolytic activity
(green) in plaques (6E10, red) and granule cells (gc) in the dentate gyrus of
5xFAD mice at 6 months. Lower panels without Hoechst staining show
that gelatinolysis is reduced in the amyloid plaque and in granule cells. The
graph shows a ∼50% reduction in gelatin-FITC signal after GM6001
incubation. Values are the mean ± SEM of four mice per group. *p < 0.05;
Student t-test.
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FIGURE 7 | Age-dependent upregulation of APP, APP CTFs and Aβ
trimers in 5xFAD hippocampi. (A) Western blot showing full-length APP
levels and the corresponding quantification, using the 22C11 antibody on
the soluble fraction of WT and 5xFAD hippocampi at 2, 4 and 6 months.
(B) Western blot and the corresponding quantifications of full-length APP,
APP CTFs (C99 and C83) and Aβ trimers using the CTF and 6E10
antibodies on membrane-enriched fractions of the same animals. Actin
normalized values are the mean ± SEM of four mice per group
representing the percentage of variation in optical density (O.D.).
*p < 0.05, **p < 0.01, when comparing 5xFAD vs. WT of the same age;
#p < 0.05, ##p < 0.01, when comparing the same genotype across age;
ANOVA followed by Tukey’s test.
close to GFP control values. Since C99 is the substrate of γ-
secretase to produce Aβ, we next investigated whether increased
C99 levels would impact Aβ formation after MT1-MMP over-
expression in HEKswe cells. The latter overproduce Aβ40 with
respect to Aβ42 and only the former is easily detected (Buggia-
Prevot et al., 2008). Moreover, it is known that Aβ42 forms
oligomers much faster than does Aβ40 (Soreghan et al., 1994).
Together, a low Aβ42/Aβ40 ratio, combined with a relatively
short post-transfection period may compromise the detection
of Aβ oligomers in these cells. Accordingly, we used a sensitive
quantitative ELISA assay to assess global soluble levels of Aβ40 as
a suitable readout of amyloidogenesis. We found that MT1-MMP-
mediated increase of C99 was concomitant with a 70% increase
of Aβ40 levels in the supernatants of HEKswe cells (Figure 8B).
On the opposite, MMP-2/GFP overexpression nearly abolished
Aβ40 production, which was decreased 88% with respect to GFP
control. Together, these data clearly underline the amyloidogenic
properties of MT1-MMP and the anti-amyloidogenic activity of
MMP-2 (Figure 8B).
DISCUSSION
The present study describes specific patterns of expression for
several MMPs at different stages of Alzheimer’s pathology in the
5xFAD mouse model. We extend previously reported data on
advanced stages of the pathology in other mouse models to show
that expression of MMP-2 and MMP-9 is mainly upregulated
in reactive astrocytes and amyloid plaques, as early as 2 months
of age and further confirmed at later stages (4 and 6 months),
suggesting their importance in the evolution of the amyloidogenic
process. Most interestingly, our data uncover the upregulation
of the active form of MT1-MMP in the 5xFAD hippocampus at
6 months, along with strong accumulation of APP C-terminal
fragment C99 and Aβ trimers. This starts at 4 months of age,
which seems to signal a stage of the pathology where APP
metabolism is suddenly accelerated in 5xFAD hippocampi. We
finally demonstrated in HEKswe cells that MT1-MMP overex-
pression increased the production of both Aβ and its precursor
C99, suggesting a possible link between increased MT1-MMP
activity in vivo and amyloidosis. In summary, we provide evidence
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FIGURE 8 | MT1-MMP and MMP-2 have opposite roles in the regulation
of C99 and Aβ in HEKswe cells. (A) Left panel, western blot using a GFP
specific antibody illustrates a representative experiment showing equivalent
levels of overexpression for MT1-MMP/GFP (MT1) and MMP-2/GFP fusion
proteins 48 h post-transfection. Right panel, western blot with the
corresponding quantification of APP C99 levels, using the CTF antibody on
whole cell lysates of HEKswe cells 48 h after transfection of plasmids coding
for GPF, MT1-MMP/GFP and MMP-2/GFP fusion proteins. Actin normalized
values are the mean ± SEM of four independent cultures representing the
percentage of variation in optical density (O.D.). **p < 0.01, MT1 vs. GFP and
MMP-2; ANOVA followed by Tukey’s test. (B) ELISA assay showing opposite
effects on Aβ40 levels in the supernatant of HEKswe cells 48 h
post-transfection. MT1-MMP significantly induced Aβ production, whereas
MMP-2 nearly abolished it. Values are the mean ± SEM of four independent
cultures. **p < 0.01, MT1 vs. GFP and MMP-2; ##p < 0.01, MMP-2 vs. GFP.
ANOVA followed by Tukey’s test.
that three MMPs potentially involved in APP/Aβ metabolism
are differentially upregulated across age in a transgenic mouse
model of AD, and among them, MT1-MMP may be a new pro-
amyloidogenic proteinase.
THE mRNA EXPRESSION OF PROTEOLYTIC SYSTEMS AND
INFLAMMATORY MARKERS IS DIFFERENTIALLY REGULATED ACROSS
THE DIFFERENT PHASES OF THE PATHOLOGY IN 5xFAD MICE.
The three stages studied underline correlations between the pro-
gression of Aβ load and pahtology. Our qPCR study reveals
that pro-inflammatory markers previously associated with AD
(e.g., Il-1β, and Ccl2) are the only genes significantly upregu-
lated at 2 months, possibly signifying the early response of the
system to incipient Aβ production. The age-dependent increases
in mRNA expression for Il-1β and Ccl2, associated with the
increase of markers of astrocyte (Gfap) and microglial (F4/80)
reactivity further comforts the widely assumed idea of a reg-
ulatory link between Aβ production and neuroinflammation.
In this context, the proteolytic systems studied displayed rather
differential profiles. While mRNA levels of major α-secretases
and Aβ-degrading enzymes remained basically unaffected, MMPs
were overall upregulated in 5xFAD mice compared to WT. Such
selective modulation of MMP gene expression may result from
the prominent ability of pro-inflammatory cytokines to stimu-
late MMPs (Fanjul-Fernández et al., 2010; Rivera et al., 2010).
Seemingly, TIMPs are also modulated by cytokines, in particular
TIMP-1, whose expression is significantly upregulated by Il-1β
(Dafnis et al., 2012). Accordingly, TIMP-1 expression increased in
5xFAD hippocampi at 4 months and thereafter, in pace with the
upregulated expression of its main targets MMP-9 and MMP-2.
While some members of the MMP/TIMP system clearly showed
upregulation of mRNA expression, the expected translation into
increased protein levels was not explicitly observed. This is partic-
ularly evident for TIMP-1, whose mRNA levels were dramatically
increased at 4 and 6 months in 5xFAD mice, while protein levels
were only significantly upregulated at 4 months. This apparent
inconsistency at 6 months could reflect adaptive mechanisms
(e.g., increased turnover of TIMP-1) set in motion to keep the
levels of TIMP-1 within a physiological range, and therefore
prevent for instance excessive inhibition of metalloproteinases
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presumably involved in AD homeostatic responses; α-secretase
ADAM-10 and Aβ-degrading enzymes MMP-2 and MMP-9 are
paradigmatic examples of TIMP-1 targets (Rivera et al., 2010).
The implementation of feedback mechanism of control between
protein and mRNA may be feasible in chronic situations such as
AD, clearly in contrast with acute brain insult (i.e., excitotoxic
seizures), where rapid and transient upregulation of TIMP-1
mRNA is followed by the subsequent increase of TIMP-1 protein
levels (Rivera et al., 1997).
DIFFERENTIAL CELL-DEPENDENT UPREGULATION OF MMPs ACROSS
AGE
Our study confirms in 5xFAD mice previous work reporting
the increase of MMP-2 and MMP-9 immunostaining in reactive
astrocytes around plaques in the APP/PS1 transgenic mouse
model of AD (Yin et al., 2006). The same study suggested that the
release of these MMPs by astrocytes contribute to Aβ degradation.
Interestingly, despite the well-reported activation of microglial
cells in 5xFAD mice (Oakley et al., 2006; Girard et al., 2013),
neither MMP-2 nor MMP-9 seemed to be associated with these
cells. In the case of MMP-9, its microglial upregulation has been
previously associated with neurotoxic effects on hippocampal
neurons (Rivera et al., 2002; Jourquin et al., 2003), indirectly sug-
gesting that activated microglia in the 2- to 6-month old 5xFAD
mice are involved in beneficial rather than detrimental processes.
By combining in situ zymography and MMP inhibition with
GM6001, we further confirmed MMP-dependent gelatinolytic
activity especially in amyloid plaques. Since MMP-9 and MT1-
MMP immunostaining were particularly prominent in amyloid
plaques, it is possible that they contribute to gelatinolysis in a
significant manner, which would be consistent with the singular
ability of both MMPs to degrade fibrillar Aβ (Yan et al., 2006; Liao
and Van Nostrand, 2010). The pathophysiological consequences
of amyloid plaque degradation by these MMPs have not been
investigated yet, and will likely depend on the cytotoxicity of
the potentially released breakdown products (e.g., oligomers). In
our study, we found upregulation of MMP-2 and MMP-9 levels
(mRNA and protein) at 4 months, while no differences were
observed between WT and 5xFAD in 2- and 6-month-old mice.
This is in contrast with the maintaining of important MMP levels
in reactive astrocytes and amyloid plaques, and may signify a
global overall increase around the prodromal phase of the pathol-
ogy, coincident with an important activation of APP metabolism.
Indeed, at 4 months of age we observe a dramatic increase of
CTFs, soluble Aβ and Aβ oligomers. The transient increase of
MMPs with Aβ-degrading activity may reflect the homeostatic
response of the organism to the increase of Aβ load. In the long
term, a sustained increase of these MMPs may not be compatible
with the preservation of neural function. In this context, MMP-9,
in particular, has been shown to be neurotoxic for hippocampal
neurons (Jourquin et al., 2003) and both MMP-2 and MMP-9 may
disturb BBB function and foster the inflammatory response (Yang
et al., 2007).
Besides amyloid plaques, MT1-MMP was primarily associ-
ated with neurons. Previous studies reported astrocytic MT1-
MMP expression in the thalamus of 24-month-old Tg-SW DI
mice, a model where the localization of fibrillar Aβ deposits
is restricted to cerebral microvessels (Liao and Van Nostrand,
2010). Another study suggested the expression of MT1-MMP
in reactive microglial cells around amyloid plaques in 5xFAD
mice slightly older than those used in the present work and in
postmortem AD brains (Langenfurth et al., 2013). Our dou-
ble immunostaining experiments failed to establish any colo-
calization of MT1-MMP with cells other than neurons in the
hippocampus over the time period studied. Differences in the
time points, the immunostaining protocols or the stage of the
pathology studied in these different works might account for
such cell-type differences. The temporal MT1-MMP profile of
expression differed with respect to MMP-2 and MMP-9. Indeed,
MT1-MMP upregulation occurred in the membrane-enriched
fraction during the symptomatic phase of the pathology at 6
months, as demonstrated by WB. Increases were observed in
the active form of MT1-MMP without significant changes in
the content of its precursor pro-MT1-MMP. We conclude from
these data that the production of pro-MT1-MMP likely increases
at 6 months, but this is efficiently cleaved by the intracellular
proprotein convertase furin to generate the active form (Mazzone
et al., 2004). Although the mechanism that triggers MT1-MMP
upregulation at 6 months remains to be elucidated, one possibility
is that the progressive age-dependent accumulation of Aβ and/or
APP stimulates the production of MT1-MMP. This appears to be
the case when human cerebrovascular smooth muscle cells are
treated with Aβ (Jung et al., 2003) or after overexpression of APP
in HEK cells (Ahmad et al., 2006).
APP AND ITS TOXIC METABOLITES INCREASE WITH AGE IN 5xFAD
MICE
Not surprisingly, the expression of the human transgene upregu-
lated the levels of APP in 5xFAD compared to WT. It is interesting
to note that 5xFAD soluble APP do not differ from WT until
4 months of age, whereas a dramatic increase of membrane
full length APP occurs as early as 2 months. This may indicate
that the release and/or turnover of soluble forms of APP are
tightly regulated in 5xFAD hippocampi. In contrast, a strong
increase of CTFs at 2 months is in pace with the accumulation
of their full-length precursor at the membrane. This finding may
be particularly relevant, since the β-secretase derived fragment
C99 has been described as an early neurotoxic metabolite of
APP that accumulates much earlier than Aβ species (Lauritzen
et al., 2012). In keeping with this idea, the increase of C99 levels
at 2 months in our 5xFAD mice is in clear contrast with the
finding that Aβ trimers could not be detected before 4 months
of age. Thus, our data further support that early accumulation
of C99 may trigger detrimental effects preceding those poten-
tially caused by neurotoxic Aβ assemblies (i.e., trimers) at later
time points.
MT1-MMP DISPLAYS AMYLOIDOGENIC FEATURES
The in vivo data argue in favor of a functional link between the
upregulation of MT1-MMP levels and amyloidosis. In support
of this hypothesis the overexpression of MT1-MMP stimulated
both C99 and Aβ production by HEKswe cells. Previous work
using wild type HEK cells demonstrated that overexpression of
both MT1-MMP and APP results in the generation of several
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soluble APP fragments with undetermined functional conse-
quences (Ahmad et al., 2006). In line with our data, one pos-
sible consequence of APP cleavage by MT1-MMP would be to
stimulate the generation of C99 and then Aβ production by γ-
secretase. However, none of the soluble APP fragments identified
in the Ahmad et al. (2006) study resulted from unambiguous β-
secretase cleavage. It is thus unlikely that C99 results from at direct
β-site cleavage of APP by MT1-MMP, and rather points out to a
modulatory effect of this MMP on the processing of APP by β-
secretase. Our data provide evidence for a new role of MT1-MMP
as a pro-amyloidogenic enzyme. However, it has been shown that
MMP overexpression in COS cells, as well as soluble MT1-MMP
are both able to degrade exogenous synthetic Aβ (Liao and Van
Nostrand, 2010). Altogether, these findings suggest the possibility
of a dual role for MT1-MMP that might depend on the location
and the way APP and Aβ are processed. The MT1-MMP-mediated
increase of C99 in HEKswe cells supports an intracellular action of
MT1-MMP, possibly stimulating amyloidogenesis via β-secretase
activity and/or modifying APP trafficking that needs to be further
evaluated. This could reflect the situation in 5xFAD neuronal
cells where MT1-MMP and APP levels increase with age, which
does not preclude a putative intrinsic capacity of MT1-MMP to
degrade exogenous Aβ. The latter would be more physiologically
compatible with situations where MT1-MMP would be produced
by surrounding glial cells that could degrade Aβ released by
neurons.
In full agreement with the literature on Aβ proteolysis (see
De Strooper, 2010; Rivera et al., 2010 for review), overexpressing
MMP-2 in our cell system nearly abolished Aβ production. This
occurred without affecting C99 levels, in clear contrast with the
effects of MT1-MMP. Both MMPs have been described to interact
with TIMP-2 in a ternary complex where MT1-MMP activates
MMP-2 (Strongin et al., 1995). In the present case, MMP-2 and
MT1-MMP seem to work independently, at least as far as the
generation of C99 and Aβ is concerned.
Our data provide evidence that the age of 4 months signals
a time for overt accumulation of Aβ trimers and C99. This
sudden activation of APP metabolism occurs at a prodromal-
like phase of the pathology, where the first cognitive deficits are
observed in 5xFAD males tested in a hippocampal-dependent
olfactory task (Girard et al., 2014), and it is maintained over
the symptomatic phase (6 months). Early accumulation (2–4
months) of Aβ 3-42 pyroglutamate, a highly toxic species of Aβ,
and axonal swelling have also been reported in the hippocampus
of 5xFAD mice (Jawhar et al., 2012; Moon et al., 2012). Together,
these data highlight the interest of studying the physiopathology
of the hippocampus in the 5xFAD mouse model, and provide
further molecular support for the impairment of hippocampal
synaptic transmission reported in 5xFAD mice (Kimura and
Ohno, 2009; Crouzin et al., 2013). Our study provides the first
evidence that different MMPs involved in APP/Aβmetabolism are
differentially regulated in a spatio-temporal manner in the 5xFAD
murine model of AD. Such upregulation is consistent with the
putative role of MMP-2 and MMP-9 as Aβ-degrading enzymes,
which could locally exert their actions once released by reactive
astrocytes in the vicinity of plaques. Most interestingly, our data
support the idea that MT1-MMP stimulates APP metabolism
and amyloidogenesis. Although the in vivo data do not prove per
se a functional link between the increase of active MT1-MMP
and Aβ accumulation, these findings, together with our in vitro
results, should set the basis to further validate a potential pro-
amyloidogenic role of MT1-MMP and characterize the molecular
mechanisms at stake.
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